RNA CARs技术在实体肿瘤中成功运用会面临的障碍

Roadblocks to success for RNA CARs in solid tumors.
While CAR therapy has begun to demonstrate efficacy, cell-engineering techniques that result in permanent genomic modification carry several safety concerns. CAR expression driven by RNA creates a platform for delivery of highly-active cell therapy while avoiding long-term CAR-driven toxicity. Using models of pediatric neuroblastoma, we have found that RNA CAR T cell activity is limited by ineffective tumor infiltration.
KEYWORDS:
GD2; Lenti CAR, lentivirally-modified chimeric antigen receptor T cell; RNA; RNA CAR, RNA-modified chimeric antigen receptor T cell; chimeric antigen receptors; pediatrics; solid tumors
RNA CARs技术在实体肿瘤中成功运用会面临的障碍
CAR治疗技术展现了其有效性，细胞修饰技术导致的永久性的基因修饰会产生严重的安全隐患。通过RNA产生CAR，不但能够构建高活性的细胞治疗能力，而且还能够避免长期的CAR导致的毒副作用。通过构建儿童神经细胞瘤的模型，我们发现RNA CAR-T细胞的活性受到无效肿瘤细胞浸润的影响。
关键词： GD2；Lenti CAR；慢病毒载体修饰的嵌合抗原受体T细胞；RNA；RNA CAR；RNA修饰的嵌合抗原受体T细胞；嵌合抗原受体; ；儿科；实体瘤
出自爱康得生物技术